NCOA1 and male reproductive organ cancer: In total, 11 out of 885 have been targeted by PrCa-specific drugs (source: DrugBank; protein targets: ESR2, ESRRA, AR, PARP1, NFKB2, NFKB1, NCOA2, NCOA1, AKT1, TOP2A, TOP2B; drugs: Estramustine, Genistein, Flutamide, Nilutamide, Bicalutamide, Enzalutamide, Olaparib, Custirsen, Amonafide); and 190 out of 885 are targets of non-prostate drugs indicating the possibility of re-purposing.